{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:15:19Z","timestamp":1768324519961,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ygyno.2015.11.005","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T05:56:11Z","timestamp":1446702971000},"page":"36-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer"],"prefix":"10.1016","volume":"140","author":[{"given":"Genevi\u00e8ve","family":"Bouchard-Fortier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iryna","family":"Vyarvelska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Pasetka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Covens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian T.","family":"Gien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Kupets","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Pulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Vicus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2015.11.005_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2015.11.005_bb0010","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"International Journal of Gynaecology and Obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics"},{"issue":"1","key":"10.1016\/j.ygyno.2015.11.005_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2015.11.005_bb0020","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.11.005_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005340.pub3","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","volume":"11","author":"Jaaback","year":"2011","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.ygyno.2015.11.005_bb0030","article-title":"Intraperitoneal chemotherapy: rationale, applications, and limitations","author":"Al-Quteimat","year":"2013","journal-title":"Journal of Oncology Pharmacy Practice: official publication of the International Society of Oncology Pharmacy Practitioners"},{"issue":"17","key":"10.1016\/j.ygyno.2015.11.005_bb0035","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2015.11.005_bb0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/bjc.1994.45","article-title":"Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin","volume":"69","author":"Los","year":"1994","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2015.11.005_bb0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/gyno.1993.1171","article-title":"Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer","volume":"50","author":"Markman","year":"1993","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2015.11.005_bb0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3802\/jgo.2012.23.2.75","article-title":"Three ongoing intraperitoneal chemotherapy trials in ovarian cancer","volume":"23","author":"Fujiwara","year":"2012","journal-title":"J. Gynecol. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.ygyno.2015.11.005_bb0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1525-1438.2007.01100.x","article-title":"National Cancer Institute\u2014United States strategy regarding intraperitoneal chemotherapy for ovarian cancer","volume":"18","author":"Trimble","year":"2008","journal-title":"International Journal of Gynecological Cancer: official journal of the International Gynecological Cancer Society."},{"issue":"3","key":"10.1016\/j.ygyno.2015.11.005_bb0060","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ygyno.2009.10.054","article-title":"Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer","volume":"116","author":"Gray","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2015.11.005_bb0065","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/bjc.1998.710","article-title":"Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group","volume":"78","author":"Aabo","year":"1998","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2015.11.005_bb0070","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ygyno.2012.08.037","volume":"127","author":"Gould","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2015.11.005_bb0075","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/IGC.0b013e3181a29dfe","article-title":"Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study","volume":"19","author":"Fujiwara","year":"2009","journal-title":"International Journal of Gynecological Cancer: official journal of the International Gynecological Cancer Society"},{"issue":"1","key":"10.1016\/j.ygyno.2015.11.005_bb0080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ygyno.2011.12.417","volume":"125","author":"Gould","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.11.005_bb0085","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2005.06.055","volume":"99","author":"Miyagi","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2015.11.005_bb0090","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/jjco\/hyq182","article-title":"A randomized phase II\/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer","volume":"41","author":"Fujiwara","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2015.11.005_bb0095","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3747\/co.v18i2.725","article-title":"Phase II\/III study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21","volume":"18","author":"Mackay","year":"2011","journal-title":"Current Oncology (Toronto, Ont.)"},{"issue":"6","key":"10.1016\/j.ygyno.2015.11.005_bb0100","doi-asserted-by":"crossref","first-page":"501.e501","DOI":"10.1016\/j.ajog.2013.03.012","article-title":"Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers","volume":"208","author":"Teefey","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.11.005_bb0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2008.11.021","article-title":"Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma","volume":"112","author":"Chin","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.11.005_bb0110","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ygyno.2012.03.027","article-title":"Progression-free and overall survival of a modified outpatient regimen of primary intravenous\/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer","volume":"125","author":"Barlin","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.ygyno.2015.11.005_bb0115","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/sj.bjc.6601693","article-title":"Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery","volume":"90","author":"Mikeljevic","year":"2004","journal-title":"Br. J. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815301773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815301773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T06:59:48Z","timestamp":1653461988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815301773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0090825815301773"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.11.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}